Hsiao D. Lieu - 11 Aug 2021 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC

Role
SVP, Chief Medical Officer
Signature
/s/ Valerie Pierce, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
11 Aug 2021
Net transactions value
-$143,454
Form type
4
Filing time
13 Aug 2021, 16:27:16 UTC
Next filing
07 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NGM Common Stock Sale $51,934 -2,258 -100% $23.00* 0 11 Aug 2021 Direct F1
transaction NGM Common Stock Options Exercise $96,480 +8,000 $12.06* 8,000 12 Aug 2021 Direct
transaction NGM Common Stock Sale $188,000 -8,000 -100% $23.50* 0 12 Aug 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGM Stock Option (Right to Buy) Options Exercise $0 -8,000 -4% $0.000000 192,000 12 Aug 2021 Common Stock 8,000 $12.06 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 183 and 1,893 shares purchased through the Issuer's employee stock purchase plan on 11/13/2020 and 5/14/2021, respectively.
F2 The shares subject to the stock option vest over a four-year period measured from the grant date, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.